Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263050 · ClinicalTrials.gov registry record · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT05263050 is a Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 111 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05263050, a Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05263050
The ClinicalTrials.gov registry entry for NCT05263050 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (38% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05263050 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05263050 about?
NCT05263050 is a clinical study titled "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors". This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
What is the current status of trial NCT05263050?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2022-01-21. Estimated completion is 2027-02.
What conditions does trial NCT05263050 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Metastatic Renal Cell Carcinoma, Carcinoid Tumor, Clear-cell Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT05263050?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05263050?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263050 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
RECRUITING · Phase 2
Explore more on PlainTrial
Neuroendocrine Tumors
All registered trials for this condition
Metastatic Renal Cell Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.